Are Peptides Legal in Maine? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Maine as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Maine attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Maine statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Maine has scheduled or banned on its own. The Maine Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Maine at a glance

State controlled-substances law: Maine Criminal Code, 17-A M.R.S. ch. 45 (§ 1101 et seq.); drug schedules W, X, Y and Z at 17-A M.R.S. § 1102 (legislature.maine.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (17-A M.R.S. § 1102 (Schedules W, X, Y and Z)) (legislature.maine.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: No Maine Board of Pharmacy rule or statement on compounded semaglutide or tirzepatide was found. The only board-level item located is a correspondence entry on the 1 August 2024 meeting agenda, a request from Novo Nordisk to take action on compounded semaglutide; no resulting board action was found (2024-08-01) (maine.gov)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. Under the Board of Licensure in Medicine's telemedicine rule (02-373 C.M.R. ch. 6, § 3) a physician-patient relationship may be formed through telemedicine if the standard of care does not require an in-person encounter, and telemedicine prescriptions carry the same accountability as in-person ones. Prescribing based solely on an internet request or a static internet questionnaire is prohibited; the interview must be adaptive and interactive, and the prescriber must hold a Maine licence. (law.cornell.edu)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Maine, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Maine:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Maine. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Maine law adds

Maine's controlled-substances law (Maine Criminal Code, 17-A M.R.S. ch. 45 (§ 1101 et seq.); drug schedules W, X, Y and Z at 17-A M.R.S. § 1102) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (legislature.maine.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Maine's schedules or in a Maine-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Maine's own schedules do not name human growth hormone, somatropin, anabolic steroids or any peptide. HGH is restricted in Maine only through federal law and its prescription-only status. (17-A M.R.S. § 1102 (Schedules W, X, Y and Z)) (legislature.maine.gov)

Compounded semaglutide and tirzepatide

2024-08-01. No Maine Board of Pharmacy rule or statement on compounded semaglutide or tirzepatide was found. The only board-level item located is a correspondence entry on the 1 August 2024 meeting agenda, a request from Novo Nordisk to take action on compounded semaglutide; no resulting board action was found. (maine.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Maine medical board guidance specific to peptide therapy was located. A Maine prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Maine

Maine's possession offence (17-A M.R.S. § 1107-A) applies only to drugs on schedules W to Z, so holding unscheduled research peptides is no Maine drug offence; no general offence for possessing a non-controlled prescription drug without a prescription was found, and the federal rules bind sellers rather than end users. (legislature.maine.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Maine is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Under the Board of Licensure in Medicine's telemedicine rule (02-373 C.M.R. ch. 6, § 3) a physician-patient relationship may be formed through telemedicine if the standard of care does not require an in-person encounter, and telemedicine prescriptions carry the same accountability as in-person ones. Prescribing based solely on an internet request or a static internet questionnaire is prohibited; the interview must be adaptive and interactive, and the prescriber must hold a Maine licence. (law.cornell.edu) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Maine law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Maine

2025-02-19. Maine's attorney general joined the 38-state letter urging the FDA to act against counterfeit and illegally sold GLP-1 drugs, including research-only sales. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. A joint Boards of Medicine, Osteopathic Medicine and Nursing rule on IV therapy and medspa practice took effect in July 2026 (reported by AmSpa); it covers compounding standards but does not mention peptides or GLP-1s. No Maine action against peptide sellers or GLP-1 clinics was found.

Frequently asked questions

Is BPC-157 legal in Maine?

Maine has not scheduled BPC-157, so possessing it is not a Maine offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Maine?

Yes. Under the Board of Licensure in Medicine's telemedicine rule (02-373 C.M.R. ch. 6, § 3) a physician-patient relationship may be formed through telemedicine if the standard of care does not require an in-person encounter, and telemedicine prescriptions carry the same accountability as in-person ones. Prescribing based solely on an internet request or a static internet questionnaire is prohibited; the interview must be adaptive and interactive, and the prescriber must hold a Maine licence. The Maine Board of Pharmacy position on compounded versions: No Maine Board of Pharmacy rule or statement on compounded semaglutide or tirzepatide was found. The only board-level item located is a correspondence entry on the 1 August 2024 meeting agenda, a request from Novo Nordisk to take action on compounded semaglutide; no resulting board action was found.

Is HGH legal in Maine?

Only with a valid prescription for an approved use. Maine does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Maine fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.